» Authors » Rene M Lemieux

Rene M Lemieux

Explore the profile of Rene M Lemieux including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 182
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen Y, Nagaraja N, Fan B, Utley L, Lemieux R, Popovici-Muller J, et al.
Drug Metab Dispos . 2021 Jul; 49(10):870-881. PMID: 34321251
Point mutations in isocitrate dehydrogenase 1 () result in conversion of -ketoglutarate to the oncometabolite, d-2-hydroxyglutarate (2-HG). Ivosidenib is a once daily (QD), orally available, potent, mutant isocitrate dehydrogenase 1...
2.
Popovici-Muller J, Lemieux R, Artin E, Saunders J, Salituro F, Travins J, et al.
ACS Med Chem Lett . 2018 Apr; 9(4):300-305. PMID: 29670690
Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells,...
3.
Horan J, Kuzmich D, Liu P, Disalvo D, Lord J, Mao C, et al.
Bioorg Med Chem Lett . 2015 Dec; 26(2):466-471. PMID: 26687487
Poor solubility and cationic amphiphilic drug-likeness were liabilities identified for a lead series of S1P3-sparing, S1P1 agonists originally developed from a high-throughput screening campaign. This work describes the subsequent optimization...
4.
Horan J, Sanyal S, Choi Y, Hill-Drzewi M, Patnaude L, Anderson S, et al.
Bioorg Med Chem Lett . 2014 Sep; 24(20):4807-11. PMID: 25241927
The discovery of a new series of selective S1P1 agonists is described. This series of piperazinyl-oxadiazole derivatives was rapidly optimized starting from high-throughput screening hit 1 to afford potent and...
5.
Lemieux R, Devine P, Mechelke M, Meyers A
J Org Chem . 2001 Oct; 64(10):3585-3591. PMID: 11674485
Sequential allylation of chiral, nonracemic thiolactam 8 affords clean thio-Claisen [3,3] products 11. The stereoselectivity of the rearrangement was found to be on the order of 10-11:1, with the exo-endo...